Xenografts Evolve Differently than Tumors

Cancer Discovery

Abstract

In a study of 1,110 patient-derived xenografts (PDX) from 24 cancer types, researchers found that the genomic landscape of these tools changes dramatically over time. Some of the genetic changes observed have been associated with drug sensitivity in previous studies, raising questions about the use of PDXs to predict drug response in personalized medicine.

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
D Hochhauser, Carlos Caldas
© 2022 Meta ULC. All rights reserved